Ahmedabad: Hester Biosciences Limited reported a 140% year-on-year rise in standalone profit after tax (PAT) at Rs 10.67 crore for the third quarter of FY26, compared to Rs 4.44 crore in the year-ago period, driven by improved execution and margin expansion.Revenue from operations grew 12% YoY to Rs 70.35 crore in Q3FY26. EBITDA increased 72% to Rs 17.75 crore, with margins expanding to 25% from 16% a year earlier. Earnings per share stood at Rs 12.54.
During the quarter, the company capitalised its fill-finish facility, effectively doubling drug product capacity and enhancing manufacturing flexibility to support future growth across domestic and export markets. Hester said it continued to maintain strong operational discipline through controlled overheads, process standardisation, and efficient manpower deployment.After the quarter-end, the company received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine, strengthening its poultry vaccine portfolio.For the nine months ended Dec 2025, standalone PAT rose 16% YoY to Rs 25.72 crore. EBITDA stood at Rs 44.46 crore, with margins improving to 22%, while revenue declined to Rs 198.42 crore amid delays in govt-led animal immunisation programmes, with execution expected to pick up in Q4.
